ASC-US in a 29-Year-Old with Discordant Cotest and Prior Abnormality
A 29-year-old woman has a liquid-based Pap result of ASC-US. Her concurrent HPV genotyping is positive for HPV-16. She reports no symptoms. Records show a Pap 14 months ago reported as LSIL, followed by a negative cotest 12 months ago. She has never had a colposcopy. The laboratory uses the 2019 ASCCP risk-based management consensus guidelines. The referring clinician calls the laboratory asking whether the ASC-US result can simply be repeated in one year because the patient 'already had a normal cotest.' The cytotechnologist who screened the slide flagged rare atypical squamous cells with no definite lesion; the pathologist concurs with ASC-US.
1. Using risk-based principles, what management does this combination of current and prior results warrant, and why is a repeat cotest in one year inappropriate?
Read the worked answer
The current result is ASC-US with HPV-16 positivity, and the patient has a documented prior LSIL within the past several years. Under risk-based management, current HPV-16 positivity with any squamous abnormality places the immediate CIN3+ risk well above the colposcopy threshold (≥4%), and a prior LSIL history further raises the estimate. HPV-16 positivity is itself a strong risk modifier; genotype-specific data show that HPV-16 confers substantially higher CIN3+ risk than other high-risk types at the same cytology. Therefore colposcopy is indicated now.
A one-year repeat cotest is not appropriate because: (1) the 'normal cotest' 12 months ago does not reset risk when a new HPV-16-positive ASC-US result appears; (2) risk-based management uses the current result plus history, not the most favorable prior result; and (3) deferring colposcopy in an HPV-16-positive patient with prior LSIL risks missing an existing high-grade lesion. Expedited treatment (loop excision) is not indicated here because the immediate risk does not reach the treatment threshold (generally ≥60% immediate CIN3+), so colposcopy with biopsy is the correct next step.
2. The clinician asks whether HPV genotyping changes anything versus a pooled high-risk HPV result. Explain the role of partial genotyping in this scenario.
Read the worked answer
Partial genotyping separates HPV-16 and HPV-18 from the pooled other high-risk types. This matters because the same cytology result carries different risk depending on genotype. For ASC-US, HPV-16 positivity pushes immediate CIN3+ risk into the colposcopy-referral range, whereas many non-16/18 high-risk genotypes with ASC-US fall into a range where one-year surveillance may be acceptable in some prior-history contexts. In this patient, knowing the result is HPV-16 rather than 'high-risk HPV positive, type unspecified' strengthens the case for immediate colposcopy and removes ambiguity. Genotyping also informs subsequent surveillance intervals: persistence of HPV-16 after a negative colposcopy warrants closer follow-up than persistence of a lower-risk genotype. The laboratory should report the specific genotype (HPV-16 positive) rather than a generic positive, because management algorithms are genotype-aware.